Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estramustine phosphate: a specific chemotherapeutic agent?

D D Von Hoff, M Rozencweig, M Slavik

    The Journal of Urology
    |April 1, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2023
    Same author

    Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2016
    Same author

    Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

    Cancer chemotherapy and pharmacology·2014
    Same author

    Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.

    European journal of cancer (Oxford, England : 1990)·2012
    Same journal

    On the Memoryless Property in Markov Models for NMIBC Cost-Effectiveness Analysis.

    The Journal of urology·2026
    Same journal

    Multi-institutional Assessment of Performance Metrics for MRI-targeted Transperineal Prostate Biopsy.

    The Journal of urology·2026
    Same journal

    Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

    The Journal of urology·2026
    Same journal

    The FDA Should Allow More BCG Strains into the US Market: How Recent Landmark Trials Expose a Regulatory Paradox.

    The Journal of urology·2026
    Same journal

    Let's Shift the Focus from Death to Life after Fournier's Gangrene.

    The Journal of urology·2026
    Same journal

    Endourology and Nephrolithiasis.

    The Journal of urology·2026
    See all related articles

    Estramustine phosphate, a nitrogen mustard derivative of estradiol, shows promise for prostate cancer treatment. While not specifically targeting estrogen-dependent tissues, it demonstrates efficacy and acceptable toxicity in clinical trials.

    Area of Science:

    • Oncology
    • Pharmacology
    • Urology

    Background:

    • Estramustine phosphate is a chemotherapeutic agent combining estradiol and a nitrogen mustard.
    • It was designed to target estrogen-dependent prostate cancer cells by delivering an alkylating agent specifically.
    • The drug's mechanism of action and targeted delivery concept require thorough evaluation.

    Purpose of the Study:

    • To review preclinical and clinical data on estramustine phosphate for prostate cancer treatment.
    • To assess the extent to which the drug's design concept of targeted delivery is fulfilled.
    • To critically examine the efficacy and toxicity of estramustine phosphate in managing prostate cancer.

    Main Methods:

    • Review of existing preclinical research and clinical trial data.

    Related Experiment Videos

  • Analysis of drug efficacy and toxicity profiles in patients with prostate cancer.
  • Evaluation of the specific release of the alkylating moiety in estrogen-dependent tissues.

    • Main Results:

    • No evidence suggests that the alkylating moiety of estramustine phosphate is specifically released in estrogen-dependent tissues.
    • Estramustine phosphate exhibits activity as a treatment for prostate cancer.
    • The drug demonstrates an acceptable toxicity profile in the context of prostate cancer therapy.

    Conclusions:

    • The hypothesized targeted delivery mechanism of estramustine phosphate is not supported by current data.
    • Estramustine phosphate is an effective treatment option for prostate cancer with manageable side effects.
    • Further clinical trials are necessary to fully establish the role of estramustine phosphate in prostate cancer management.